Support Burnet’s Adolescent Health Programs in Myanmar today.
November, 2020 (1)
- Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, Jarman M, Lee T, Huang H, Chan A, Lai M, Sundararajan V, Doyle JS, Hellard M, Stoove M, Howell J, Desmond P, Iser D, Thompson A
PLoS One. 2020 Nov; 15(11):e0242101
October, 2020 (4)
- A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C.
Ramsay J, Marsh J, Pedrana A, Andric N, Norman R, Cheng W, Webb S, Zeps N, Bellgard M, Graves T, Hellard M, Snelling T
BMC Infect Dis. 2020 Oct; 20(1):802
- Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study.
Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M; TAP study group
Int J Drug Policy. 2020 Oct; 87:102983
- Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial.
Doyle JS, van Santen DK, Iser D, Sasadeusz J, O'Reilly M, Harney B, Traeger MW, Roney J, Cutts JC, Bowring AL, Winter R, Medland N, Fairley CK, Moore R, Tee B, Asselin J, El-Hayek C, Hoy JF, Matthews GV, Prins M, Stoové MA, Hellard ME
Clin Infect Dis. 2020 Oct; Epub ahead of print
- South Sudanese Perceptions of Health and Illness in South Australia.
Mude WW, Fisher CM, Le Gautier R, Wallace JM, Richmond J
Int J Migrat Health Soc Care. 2020 Oct; Accepted for publication
September, 2020 (2)
- Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.
Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, MacQuillan G, Dore GJ, Wade AJ, George J, Hazeldine S, O'Beirne J, Wigg A, Fisher L, McGarity B, Sawhney R, Sinclair M, Thomas J, Valiozis I, Weltman M, Wilson M, Woodward A, Ahlenstiel G, Haque M, Levy M, Prewett E, Sievert W, Sood S, Tse E, Valaydon Z, Bowden S, Douglas M, New K, O'Keefe J, Hellard M, Doyle J, Stoové M, Thompson AJ
Clin Infect Dis. 2020 Sep; Epub ahead of print
- Authors' response to Letter to the Editor: "Colombian experience in the management of hepatitis C".
Schroeder S, Pedrana A, Scott N, Hellard M
Liver Int. 2020 Sep; Epub ahead of print
August, 2020 (5)
- Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV).
Byrne C, Radley A, Inglis SK, Beer LJZ, Palmer N, Pham MD, Healy B, Doyle JS, Donnan P, Dillon JF
BMJ Open. 2020 Aug; 10(8):e036501
- In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
Wade AJ, Doyle JS, Draper B, Howell J, Iser D, Roberts SK, Kemp W, Thompson AJ, Hellard ME
J Viral Hepat. 2020 Aug; Epub ahead of print
- The impact of markers of HIV infection on change in liver stiffness in people with HIV and hepatitis C virus co-infection after treatment and cure of hepatitis C.
van Santen DK, Agius PA, Sasadeusz J, Fairley KC, Sievert W, Gane E, Iser D, O'Reilly M, Medland NA, Moore R, Hellard ME, Hoy JF, Doyle JS
J Acquir Immune Defic Syndr. 2020 Aug; 85(5):e81-e89
- Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England.
Mohamed Z, Scott N, Al-Kurdi D, Selvapatt N, Thursz MR, Lemoine M, Brown AS, Nayagam S.
Liver Int. 2020 Aug; Epub ahead of print
- Understanding 'risk' in families living with mixed blood-borne viral infection status: The doing and undoing of 'difference'.
Persson A, Smith AK, Wallace J, Valentine K, Bryant J, Hamilton M, Newman CE
Health (London). 2020 Aug; Epub ahead of print
July, 2020 (5)
- Global hepatitis C elimination: an investment framework.
Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M
Lancet Gastroenterol Hepatol. 2020 Jul; 5(10):927-939
- A model of the economic benefits of global hepatitis C elimination: an investment case.
Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, Wilson DP, Hellard M
Lancet Gastroenterol Hepatol. 2020 Jul; 5(10):940-947
- Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study.
Draper BL, Pedrana A, Howell J, Yee WL, Htay H, Aung KS, Shilton S, Kyi KP, Naing W, Hellard M
JMIR Res Protoc. 2020 Jul; 9(7):e16863
- Achieving Hepatitis C Elimination By Using Person-Centered, Nurse-Led Models of Care: A Discussion of Four International Case Studies.
Richmond JA, Gallagher L, McDonald L, OʼSullivan M, Fitzsimmons C, Pedrana A
Gastroenterol Nurs. 2020 Jul; 43(4):303-309
- Hepatitis C elimination in people living with HIV - the importance of biomedical and behavioural interventions.
van Santen DK, Sacks-Davis R, Hellard M
J Int AIDS Soc. 2020 Jul; 23(7):e25589
June, 2020 (4)
- The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
Traeger MW, Pedrana AE, van Santen DK, Doyle JS, Howell J, Thompson AJ, El-Hayek C, Asselin J, Polkinghorne V, Membrey D, Bramwell F, Carter A, Guy R, Stoové MA, Hellard ME; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
PLoS One. 2020 Jun; 15(6):e0235445
- Privacy-Preserving Record Linkage of Deidentified Records Within a Public Health Surveillance System: Evaluation Study.
Nguyen L, Stoové M, Boyle D, Callander D, McManus H, Asselin J, Guy R, Donovan B, Hellard M, El-Hayek C
J Med Internet Res. 2020 Jun; 22(6):e16757
- Can community pharmacists treat hepatitis C virus?
Lancet Gastroenterol Hepatol. 2020 Jun; 5(9):790-791
- Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
Semá Baltazar C, Boothe M, Kellogg T, Ricardo P, Sathane I, Fazito E, Raymond HF, Temmerman M, Luchters S
BMC Public Health. 2020 Jun; 20(1):851
May, 2020 (2)
- Striving for hepatitis C elimination - the role of a vaccine.
Hellard M, Drummer H, Scott N
Clin Infect Dis. 2020 May; Epub ahead of print
- High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Zhang M, O'Keefe D, Iwamoto M, Sann K, Kien A, Hang V, Brucker C, Jolivet P, Ly S, Chhit D, Balkan S, Marquardt T, Le Paih M, Dousset JP
J Viral Hepat. 2020 May; 27(9):886-895
April, 2020 (1)
- Enhancing the antigenicity and immunogenicity of monomeric forms of hepatitis C virus E2 for use as a preventive vaccine.
Center RJ, Boo I, Phu L, McGregor J, Poumbourios P, Drummer HE
J Biol Chem. 2020 Apr; 295(21):7179-7192
March, 2020 (3)
- Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
van Santen DK, Sacks-Davis R, Doyle JS, Scott N, Prins M, Hellard M
J Viral Hepat. 2020 Mar; 27(8):770-773
- Australia needs to increase testing to achieve hepatitis C elimination.
Scott N, Sacks-Davis R, Wade AJ, Stoové M, Pedrana A, Doyle JS, Thompson AJ, Wilson DP, Hellard ME
Med J Aust. 2020 Mar; 212(8):365-370
- Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs.
Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J
Clin Infect Dis. 2020 Mar; Epub ahead of print
February, 2020 (2)
- Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
Scott N, Mohamed Z, Rwegasha J, Mbwambo J, Lemoine M, Hellard M
Int J Drug Policy. 2020 Feb; Epub ahead of print:102634
- A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
Int J Drug Policy. 2020 Feb; 76:102633
January, 2020 (13)
- Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection.
Scott N, Snell G, Westall G, Pilcher D, Raggatt M, Walker RG, Hellard M, Peleg AY, Doyle J
Sci Rep. 2020 Jan; 10(1):1459
- Maintaining the healthy body: Blood management and hepatitis C prevention among men who inject performance and image-enhancing drugs.
Fomiatti R, Lenton E, Latham JR, Fraser S, Moore D, Seear K, Aitken C
Int J Drug Policy. 2020 Jan; 75:102592
- Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Harrod ME, Byrne J, Bath N, Read P, Edwards M, Gorton C, Hayllar J, Cock V, Peterson S, Thomson C, Weltman M, Jefferies M, Wood W, Haber P, Ezard N, Martinello M, Maher L, Dore GJ; LiveRLife Study Group.
J Viral Hepat. 2020 Jan; 27(3):281-293
- Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure.
Stoové M, Wallace J, Higgs P, Pedrana A, Goutzamanis S, Latham N, Scott N, Treloar C, Crawford S, Doyle J, Hellard M
Int J Drug Policy. 2020 Jan; 75:102596
- Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.
Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; InC3 Collaborative.
Clin Infect Dis. 2020 Jan; 70(1):123-131
- B cell immunodominance in primary hepatitis C virus infection.
Brasher NA, Eltahla AA, Underwood A, Boo I, Rizzetto S, Walker M, Rodrigo C, Luciani F, Maher L, Drummer HE, Tedla N, Lloyd AR, Bull RA
J Hepatol. 2020 Jan; 72(4):670-679
- The Elimination of Hepatitis C as a Public Health Threat.
Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C
Cold Spring Harb Perspect Med. 2020 Jan; 10(4):a036939
- Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies.
Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J
Clin Infect Dis. 2020 Jan; 70(11):2369–2376
- Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
Gunn J, Higgs P
Res Social Adm Pharm. 2020 Jan; 16(9):1298-1301
- Commentary on Barre et al. (2019): Identifying remaining barriers to hepatitis C treatment in the DAA era.
Sacks-Davis R, van Santen DK, DoyleJS
Addiction. 2020 Jan; 115(3):583-584
- Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.
Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, 7, 8, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV; CEASE study team
Clin Infect Dis. 2020 Jan; 71(6):1502-1510
- Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Clin Infect Dis. 2020 Jan; 70(9):1900-1906
- Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.
Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J
Clin Infect Dis. 2020 Jan; 71(7):E115-E124
- Executive (0)
- Healthy Mothers, Healthy Babies (HMHB) (0)
- Eliminate HIV (30)
- Strategic Funding & Partnerships Executive Team (0)
- Disease Elimination (223)
- Maternal, Child and Adolescent Health (175)
- Philanthropy and Supporter Engagement (0)
- Eliminate Viral Hepatitis (33)
- Behaviours and Health Risks (132)
- Eliminate Malaria (19)
- Finance (0)
- Health Security (97)
- Eliminate Tuberculosis (TB) (5)
- Human Resources (0)
- Healthy Ageing (0)
- Research Support and Facilities (0)
- Information Technology (0)
- Laboratory Services (0)
- Education & Training (0)
- Support Services Group (0)
- Project Management and Quality Assurance Office (0)
- Previous Research and Public Health Projects (0)
- Marketing and Communications (0)
- International Operations (2)
- HIV and AIDS (50)
- Sexually Transmitted Infections (STIs) (9)
- Maternal and Child Health (56)
- Malaria (34)
- Immune Disease and Cancer (8)
- Hepatitis B (15)
- Hepatitis C (42)
- Global infectious disease threats (5)
- Injecting Drug Use (30)
- Healthy Ageing (1)
- Alcohol and Other Drugs (16)
- Tuberculosis (TB) (6)
- Young People's Health (16)
- Justice Health (3)
- Nutrition (2)
- Sexual and Reproductive Health (11)
- Infectious Disease Modelling (5)
- Infectious Diseases Surveillance (2)
- LGBTQIA+ (6)
- Influenza (2)
- Global Adolescent Health (6)
- Antimicrobial resistance (2)
- COVID-19 (novel coronavirus) (32)